The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Bruno Vergès

Service Endocrinologie

Diabétologie et Maladies Métaboliques

Hôpital du Bocage

CHU, 21000 Dijon

France

[email]@chu-dijon.fr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Service Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital du Bocage, CHU, 21000 Dijon, France. 2001 - 2012
  • Dijon Université Hôpital, Dijon, France. 2012
  • Department of Endocrinology, University Hospital, 21000 Dijon, France. 2002 - 2005

References

  1. Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein b100 catabolism in type 2 diabetes mellitus. Vergès, B., Guiu, B., Cercueil, J.P., Duvillard, L., Robin, I., Buffier, P., Bouillet, B., Aho, S., Brindisi, M.C., Petit, J.M. Arterioscler. Thromb. Vasc. Biol. (2012) [Pubmed]
  2. Strategies for insulin initiation: insights from the French LIGHT observational study. Vergès, B., Brun, J.M., Tawil, C., Alexandre, B., Kerlan, V. Diabetes Metab. Res. Rev. (2012) [Pubmed]
  3. Combination lipid therapy in type 2 diabetes mellitus. Vergès, B. Expert. Opin. Pharmacother (2011) [Pubmed]
  4. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Vergès, B. Atherosclerosis (2010) [Pubmed]
  5. Lipid modification in type 2 diabetes: the role of LDL and HDL. Vergès, B. Fundam. Clin. Pharmacol (2009) [Pubmed]
  6. Lipid disorders in type 1 diabetes. Vergès, B. Diabetes Metab. (2009) [Pubmed]
  7. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. Vergès, B., Florentin, E., Baillot-Rudoni, S., Petit, J.M., Brindisi, M.C., Pais de Barros, J.P., Lagrost, L., Gambert, P., Duvillard, L. J. Lipid Res. (2009) [Pubmed]
  8. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Vergès, B., Florentin, E., Baillot-Rudoni, S., Monier, S., Petit, J.M., Rageot, D., Gambert, P., Duvillard, L. Diabetologia (2008) [Pubmed]
  9. Plasma N-terminal Pro-Brain Natriuretic Peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes. Vergès, B., Zeller, M., Beer, J.C., Cottin, Y. Diabetes Metab. (2008) [Pubmed]
  10. Impact of fasting glycemia on short-term prognosis after acute myocardial infarction. Vergès, B., Zeller, M., Dentan, G., Beer, J.C., Laurent, Y., Janin-Manificat, L., Makki, H., Wolf, J.E., Cottin, Y. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  11. Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels. Vergès, B. Fundam. Clin. Pharmacol (2007) [Pubmed]
  12. Adiponectin is an important determinant of apoA-I catabolism. Vergès, B., Petit, J.M., Duvillard, L., Dautin, G., Florentin, E., Galland, F., Gambert, P. Arterioscler. Thromb. Vasc. Biol. (2006) [Pubmed]
  13. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Vergès, B. Curr. Opin. Lipidol. (2006) [Pubmed]
  14. Diabetic dyslipidaemia: insights for optimizing patient management. Vergès, B. Curr. Med. Res. Opin (2005) [Pubmed]
  15. High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock. Vergès, B., Zeller, M., Desgrès, J., Dentan, G., Laurent, Y., Janin-Manificat, L., L'Huillier, I., Rioufol, G., Beer, J.C., Makki, H., Rochette, L., Gambert, P., Cottin, Y. Eur. Heart J. (2005) [Pubmed]
  16. Role for fibrate therapy in diabetes: evidence before FIELD. Vergès, B. Curr. Opin. Lipidol. (2005) [Pubmed]
  17. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Vergès, B. Diabetes Metab. (2005) [Pubmed]
  18. Clinical interest of PPARs ligands. Vergès, B. Diabetes Metab. (2004) [Pubmed]
  19. Effects of cardiac rehabilitation on exercise capacity in Type 2 diabetic patients with coronary artery disease. Vergès, B., Patois-Vergès, B., Cohen, M., Lucas, B., Galland-Jos, C., Casillas, J.M. Diabet. Med. (2004) [Pubmed]
  20. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Vergès, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C., Calender, A. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  21. The impact of prandial glucose regulation in practice. Vergès, B. Diabetes Nutr. Metab. (2002) [Pubmed]
  22. Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. Vergès, B., Guerci, B., Durlach, V., Galland-Jos, C., Paul, J.L., Lagrost, L., Gambert, P. J. Lipid Res. (2001) [Pubmed]
 
WikiGenes - Universities